RxDoctor Payments Data

Ashley Laughlin

Family · Canton, OHNPI 1760866768

Payments from drug & device makers

$10,428in general payments, 2019–2025

Across 338 payments — averaging $30.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Almatica Pharma LLC$5K
  • Axsome Therapeutics, Inc.$981
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$761
  • Supernus Pharmaceuticals, Inc.$524
  • Alkermes, Inc.$455
  • Teva Pharmaceuticals USA, Inc.$427
  • plus $3K from 17 others

What the payments were for

  • Speaking & faculty fees$4,55544%
  • Food & beverage$5,87356%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,428 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$10,347
Medicare patients
18
Services billed
130

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole26$39,574
AuvelityDextromethorphan Hbr/Bupropion20$18,099
CaplytaLumateperone Tosylate11$17,800
Loreev XrLorazepam21$10,276
Aripiprazole32$1,178
Desvenlafaxine Succinate ErDesvenlafaxine Succinate32$999
Oxcarbazepine11$553
Doxepin Hcl12$456
Buspirone Hcl54$455
Duloxetine Hcl24$434
Lamotrigine44$405
Sertraline Hcl32$313
Quetiapine Fumarate17$288
Fluoxetine Hcl24$270
Bupropion XlBupropion Hcl21$258

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$235$39,57426 claims
Axsome Therapeutics, Inc.Auvelity$981$18,09920 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$761$17,80011 claims
Almatica Pharma LLCLoreev Xr, Sertraline Hcl$4,688$10,58953 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.

Other family in Canton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →